Patient Enrolment Completed for INSIGHT-003

Core Insights - Immutep Limited has completed patient enrolment in the INSIGHT-003 trial, which is evaluating the combination of eftilagimod alpha (efti) with KEYTRUDA® and doublet chemotherapy for advanced non-squamous non-small cell lung cancer [1][7] - The Phase I trial has successfully enrolled approximately 50 evaluable patients across multiple clinical sites in Germany [2] - Initial Overall Survival results from INSIGHT-003 indicate a median Overall Survival of 32.9 months and a 24-month Overall Survival rate of 81.0%, which is significantly better than the 22.0-month median OS and 24-month OS rate of 45.5% from a registrational trial of anti-PD-1 and doublet chemotherapy [3][6] - Additional data updates from INSIGHT-003 are anticipated in 2025 and beyond [3][7] Company Overview - Immutep is a clinical-stage biotechnology company focused on developing novel LAG-3 immunotherapies for cancer and autoimmune diseases [5] - The company is recognized for its pioneering work in LAG-3 therapeutics, aiming to provide innovative treatment options and maximize shareholder value [5]